CStone Pharmaceuticals Accounts Payable

CStone Pharmaceuticals (CSPHF) currently reports a accounts payable of $99M as of June 2026. That compares with $210M in the prior-year period — down 53.3% year over year. Use the charts on this page to explore CStone Pharmaceuticals's accounts payable history and peer comparisons.

CStone Pharmaceuticals's accounts payable decreased from $210M to $99M — a 53.3% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

CStone Pharmaceuticals reported $99M in accounts payable as of June 2026. That compares with $210M in the prior-year period — down 53.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $99M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for CStone Pharmaceuticals, and consider following CSPHF for alerts when major investors trade the stock.

CStone Pharmaceuticals is classified in the Healthcare sector. On accounts payable, it currently shows $99M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CSPHF with unrelated industries.